Cardiac systolic time intervals and thyroid hormone levels during treatment of hypothyroidism

References

• Crowley W F, Ridgway E C, Bough E W, Francis G S, Daniels G H, Kourides I A, Myers G S, Maloof F. Noninvasive evaluation of cardiac function in hypothyroidism. N Engl J Med 1977; 296: 1–6
   PubMed Web of Science ®Google Scholar
• Ridgway E C, Cooper D S, Walker H, Daniels G H, Chin W W, Myers G, Maloof F. Therapy of primary hypothyroidism with L-triiodothyronine: discordant cardiac and pituitary responses. Clin Endocrin 1980; 13: 479–88
   PubMed Web of Science ®Google Scholar
• Hillis W S, Bremner W F, Lawrie T DV, Thomson J A. Systolic time intervals in thyroid disease. Clin Endocrinol (Oxt) 1975; 4: 617–24
   PubMed Web of Science ®Google Scholar
• Salmi J, Lamberg B-A, Ebeling P. Absence of TRH-response to TRH and measurement of systolic time intervals for the assessment of the optimal thyroxine doses in the treatment of patients with differentiated thyroid carcinoma. Advances in Thyroid Neoplasia, M Andreoli, F Monaco, J Robbins. Field Education, RomaItaly 1981; 317–23
   Google Scholar
• Carr D, McLeod D T, Parry G, Thornes H M. Fine adjustment of thyroxine replacement dosage: comparison of the thyrotrophin releasing hormone test using a sensitive thyrotropin assay with measurement of free thyroid hormones and clinical assessment. Clin Endocrin 1988; 28: 325–33
   PubMed Web of Science ®Google Scholar
• Featherstone L H, Stewart D K. Angina in thyrotoxicosis. Arch Intern Med 1983; 143: 554–5
   PubMedGoogle Scholar
• Ikram H. The nature and prognosis of thyrotoxic heart disease. Q J Med 1985; 54: 19–28
   PubMedGoogle Scholar
• Ross D S, Neer R M, Ridgway E C, Daniels G H. Subclinical hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary-thyroid axis with L-thyroxine. Am J Med 1987; 82: 1167–70
   PubMed Web of Science ®Google Scholar
• Paul T L, Kerrigan J, Kelly A M, Bravcrman L E, Baran D T. Long-term L-thyroxine therapy is associated with decreased hip bone density in premenopausal women. JAMA 1988; 259: 3137–41
   PubMed Web of Science ®Google Scholar
• Franklyn J A, Sheppard M C. Thyroxine replacement treatment and osteoporosis. Brit Med J 1990; 300: 693–4
   PubMedGoogle Scholar
• Tunbridge W MG, Evered D C, Hall R. Lipid profiles and cardiovascular disease in the Wickham area with particular reference to thyroid failure. Clin Endocrinol 1977; 7: 495–508
   PubMed Web of Science ®Google Scholar
• Bastenic P A, Bonnyns M, Vanhaelst L. Grades of subclinieal hypothyroidism in asymptomatic autoimmune thyroiditis revealed by the thyrotrophin-releasing hormone test. J Clin Endocrinol Metab 1980; 51: 163–6
   PubMed Web of Science ®Google Scholar
• Billewicz W Z, Chapman R S, Crooks J, Day M E, Gossage J, Wayne E, Young J A. Statistical methods applied to the diagnosis of hypothyroidism. Q J Med 1969; 28: 255–66
   Google Scholar
• Wayne E J. Clinical and metabolic studies in thryoid disease. Br Med J 1960; i: 1–11; 78–90
   Google Scholar
• Soppi E, Irjala K, Kaihola H-L, Viikari J. Acute effect of exogenous thyroxine dose on serum thyroxine and thyrotrophin levels in treated hypo-thyroid patients. Scand J Clin Lab Invest 1984; 44: 347–50
   PubMed Web of Science ®Google Scholar
• Swift A D, Bruce S E, Ratcliffe J G. Comparative evaluation of high sensitive thyroid stimulating hormone assay kits. DHSS. April, 1986, Report (STB/86/17)
   Google Scholar
• Weissler A M, Harris W S, Schoenfeld C D. Bedside technics for the evaluation of ventricular function in man. Am J Cardiol 1969; 23: 577–83
   PubMed Web of Science ®Google Scholar
• SAS Institute. SAS/STAT. Guide for personal computers, 6 edn. SAS Institute, Cary, North Carolina 1987
   Google Scholar
• Brown M E, Refetoff S. Transient elevation of serum thyroid hormone concentration after initiation of replacement therapy in myxedema. Ann Intern Med 1980; 92: 491–5
   PubMed Web of Science ®Google Scholar
• Gow S M, Caldwell G, Toft A, Seth J, Hussey A, Sweeting V, Beckett G. Relationship between pituitary and other target organ responsiveness in hypothyroid patients receiving thyroxine replacement. J Clin Endocrinol Metab 1987; 64: 364–70
   PubMed Web of Science ®Google Scholar
• Hylander B, Rosenquist U. Peripheral responses to thyroxine in hypothyroid subjects as a function of dose and duration of substitution. Acta Med Scand 1983; 214: 317–23
   PubMedGoogle Scholar
• Tseng K H, Walfish P G, Persaud J A, Gilbert B W. Concurrent aortic and mitral valve echocardiography permits measurement of systolic time intervals as an index of peripheral tissue thyroid functional status. J Clin Endocrinol Metab 1989; 69: 633–8
   PubMed Web of Science ®Google Scholar
• Fraser W D, Biggart E M, O'Reilly D SC, Gray H W, McKillop J H, Thomson J A. Are biochemical tests of thyroid function of any value in monitoring patients receiving thyroxine replacement. Br Med J 1986; 293: 808–10
   PubMedGoogle Scholar
• Jennings P E, O'Malley B P, Griffin K E, Northover B, Rosenthal F D. Relevance of increased serum thyroxine concentrations associated with normal serum triiodothyronine values in hypothyroid patients receiving thyroxine: a case for tissue thyrotoxicosis. Br Med J 1984; 289: 1645–7
   PubMedGoogle Scholar
• Toft A D. Thyroxine replacement therapy. Clin Endocrinol 1991; 34: 103–5
   PubMed Web of Science ®Google Scholar
• Ross D S. Subclinical hyperthyroidism: possible danger of overzcalous thyroxine replacement therapy. Mayo Clin Proc 1988; 63: 1223–9
   PubMed Web of Science ®Google Scholar
• Watts N B. Use of a sensitive thyrotropin assay for monitoring treatment with levothyroxine. Arch Intern Med 1989; 149: 309–12
   PubMedGoogle Scholar
• Larsen P R. Thyroid-pituitary interaction feedback regulation of thyrotropin secretion by thyroid hormones. N Engl J Med 1982; 306: 32–32
   PubMed Web of Science ®Google Scholar
• Wong M M, Volpe R. What is the best test for monitoring levothyroxine therapy. Can Med Assoc J 1981; 124: 1181–3
   PubMed Web of Science ®Google Scholar
• Salmon D, Rendell M, Williams J, Smith C, Ross D A, Waud J M, Howard J E. ‘Chemical hyper-thyroidism’: serum triiodothyronine levels in clinically euthyroid individuals treated with levothyroxine. Arch Intern Med 1982; 142: 571–3
   PubMedGoogle Scholar
• Liewendahl K, Helenius T, Lamberg B-A, Mähönen H, Wägar G. Free thyroxine free triiodothyronine and thyrotropin concentrations in hypo-thyroid and thyroid carcinoma patients receiving thyroxine therapy. Acta Endocrinol (Copenh) 1987; 116: 418–24
   PubMedGoogle Scholar
• Grund F M, Niewoehner C B. Hyperthyroxinemia in patients receiving thyroid replacement therapy. Arch Intern Med 1989; 149: 921–4
   PubMedGoogle Scholar
• Nuutila P, Koskinen P, Irjala K, Linko L, Kaihola H-L, Eskola J U, Erkkola R, Seppälä P, Viikari J. Two new two-step immunoassays for free thyroxin evaluated: solid phase radioimmunoassay and time-resolved fluoroimmunoassay. Clin Chem 1990; 35: 1355–60
   Google Scholar
• Nyström E, Lundberg P-A, Petersen K, Bengtsson C, Lindstedt G. Evidence for a slow tissue adaptation to circulating thyroxine in patients with chronic L-thyroxine treatment. Clin Endocrinol 1989; 31: 143–50
   PubMed Web of Science ®Google Scholar